Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
Author:
Funder
Merck Sharp & Dohme Corp.
Merck & Co., Inc.
Merck Sharp and Dohme
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference30 articles.
1. Triple-negative breast cancer;Foulkes;N Engl J Med,2010
2. Triple-negative breast cancer: clinical features and patterns of recurrence;Dent;Clin Cancer Res,2007
3. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer;Liedtke;J Clin Oncol,2008
4. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet,2014
5. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial;von Minckwitz;Lancet Oncol,2014
Cited by 245 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Lnc00113 promotes triple‐negative breast cancer progression via the NOB‐1/MAPK signaling axis;The Journal of Gene Medicine;2024-02
2. High tumor infiltrating lymphocytes are significantly associated with pathological complete response in triple negative breast cancer treated with neoadjuvant KEYNOTE-522 chemoimmunotherapy;Breast Cancer Research and Treatment;2024-01-30
3. Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response;Breast Cancer Research;2024-01-29
4. Characterization of immunomodulating agents from Staphylococcus aureus for priming immunotherapy in triple-negative breast cancers;Scientific Reports;2024-01-08
5. Endogenous Signaling Molecule Activating (ESMA) CARs: A Novel CAR Design Showing a Favorable Risk to Potency Ratio for the Treatment of Triple Negative Breast Cancer;International Journal of Molecular Sciences;2024-01-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3